ZNF148, zinc finger protein 148, 7707

N. diseases: 81; N. variants: 2
Disease: Liver carcinoma ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.080 Biomarker disease BEFREE Resolving the current controversies will advance the development of ZBP-89 for anti-HCC therapy. 30142986 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.080 AlteredExpression disease BEFREE Additionally, high ZBP-89 expression in peritumoral HCC tissue was positively associated with the presence of liver cirrhosis. 29731904 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.080 AlteredExpression disease BEFREE We downloaded TCGA hepatocellular carcinoma (HCC) cohort data to analysis the association of Bak transcription level with ZBP-89 and Sp proteins transcription level. 29653560 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.080 Biomarker disease BEFREE Epigenetic upregulation of Bak by ZBP-89 inhibits the growth of hepatocellular carcinoma. 23954442 2013
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.080 GeneticVariation disease BEFREE Furthermore, p53(G245D) was shown to have a similar pattern of subcellular localization to ZBP-89 in tissues of HCC patients in Hong Kong. 22214764 2012
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.080 AlteredExpression disease BEFREE High ZBP-89 expression tended to be more common in World Health Organization (WHO) grade I than grades II-IV HCC. 22372401 2012
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.080 AlteredExpression disease BEFREE ZBP-89 enhances Bak expression and causes apoptosis in hepatocellular carcinoma cells. 20850481 2011
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.080 Biomarker disease BEFREE Therefore, co-localization of p53 protein with ZBP-89 may define a subgroup of recurrent HCC that is more sensitive to treatment. 12759240 2003
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.080 Biomarker disease LHGDN Therefore, co-localization of p53 protein with ZBP-89 may define a subgroup of recurrent HCC that is more sensitive to treatment. 12759240 2003